Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807558 · ClinicalTrials.gov registry record · Phase 2
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
A Phase 2 study, sponsored by Syros Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT02807558 is a Phase 2 study that has completed, run by Syros Pharmaceuticals. The registered enrollment target is 155 participants.
The verdict
NCT02807558, a Phase 2 study, has completed, sponsored by Syros Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS) (administered as a monotherapy or in combination with daratumumab), newly diagnosed treatment naïve AML participants who are unlikely to tolerate standard intensive chemotherapy (administered as a monotherapy or in combination with azacitidine), or lower-risk MDS (LR-MDS) (administered as a monotherapy).
Interventions
- DRUG Azacitidine
- DRUG Daratumumab
- DRUG Tamibarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2023-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807558
The ClinicalTrials.gov registry entry for NCT02807558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syros Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT02807558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02807558 about?
NCT02807558 is a clinical study titled "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome". The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS) (administered as a monotherapy or in combination with daratumumab), newly diagnos...
What is the current status of trial NCT02807558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2016-09-20. Estimated completion is 2023-01-25.
What interventions are being tested in trial NCT02807558?
The interventions under investigation include: Azacitidine (DRUG), Daratumumab (DRUG), Tamibarotene (DRUG).
Who is sponsoring clinical trial NCT02807558?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.